צמיחת רווחי EPS רבעונית pliantrx.com (PLRX)
The quarterly EPS growth rate helps identify seasonal profit cycles, and its current value is 8.20. High barriers to entry in the fibrosis sector are ensured by patents and costly multi-year trials. The team at Pliant Therapeutics (PLRX) enjoys market confidence, while an academic approach to R&D is supported by generous stock option programs to retain rare specialists.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_PLRX_-_Pliant-Therapeutics_-_Year-over-year-earnings-per-share-growth-for-the-last-12-months "PLRX: צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Pliant Therapeutics, Inc. 04.07.2022 - 15.11.2026 | 👁️GURU.Markets👁️")
pliantrx.com (PLRX) - פילוחי מדדים ודוחות פיננסיים
Pliant Therapeutics (PLRX) maintains liquidity through strategic partnerships with pharmaceutical behemoths, enabling the funding of fibrosis research without depleting capital. By analyzing quarterly earnings per share (EPS) dynamics, an investor assesses the rate of change in net income over three months, where any fundamental contraction of the metric signals loss risks and a decline in the company's business model efficiency.
